Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)

Clinical trial NCT06094101 · RECRUITING

Trial details

NCT number: NCT06094101
Sponsor: University Hospital Tuebingen
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Ewing Sarcoma Rhabdomyosarcoma Synovial Sarcoma

Start date: 2023-09-19
Primary completion: 2027-06-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.